Literature DB >> 10028928

Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias.

S C Verduyn1, M A Vos, H D Leunissen, J M van Opstal, H J Wellens.   

Abstract

In the anesthetized dog with complete chronic AV block (CAVB), we evaluated and compared the acute electrophysiologic effects of dronedarone i.v. (Dron, 2 times 2.5 mg/kg/10 min) and amiodarone i.v. (Amio, 2 times 5 mg/kg/10 min). This canine model with a high sensitivity for acquired torsade de pointes (TdP) provides an ideal substrate to evaluate ventricular repolarization abnormalities. Six ECG leads and two endocardial monophasic action potential (MAP) recordings in the left and right ventricle (LV and RV) were simultaneously recorded to measure QT time, action-potential duration (APD), interventricular dispersion (deltaAPD = LV(APD) - RV(APD)), early afterdepolarizations (EADs), ectopic beats (EBs), and TdP. Measurements were made at the spontaneous idioventricular rhythm (IVR) and 1,000-ms steady-state pacing. To investigate its short-term, antiarrhythmic properties, Dron was given after almokalant (0.12 mg/kg)-induced TdP. Furthermore, in another set of experiments, oral Dron (20 mg/kg, b.i.d) was given for 3 weeks to conscious CAVB dogs. Dron, i.v., shortened ventricular repolarization (QT, 435 +/- 60 to 360 +/- 55; LV(APD) 395 +/- 75 to 335 +/- 60 ms; p < 0.05), whereas IVR and ventricular effective refractory period (VERP, 225 +/- 30 to 230 +/- 30 ms) remained similar. Therefore the VERP/QT ratio increased (0.55 +/- 0.04 to 0.61 +/- 0.03; p < 0.05). Similar results were obtained with Amio, i.v.. Almokalant-induced TdP was characterized by an increased repolarization duration, deltaAPD, and EADs. Dron, i.v., suppressed the EADs, EBs, and TdP by a reduction and homogenization of repolarization (LV(APD), 505 +/- 110 to 455 +/- 80 ms, and deltaAPD, 110 +/- 55 to 65 +/- 40 ms). Long-term oral Dron increased the PP interval, CL-IVR, and QT(c) time. In contrast to oral treatment, Dron i.v. shortens ventricular repolarization parameters, resulting in suppression of EAD-dependent acquired TdP. The increased VERP/QT ratio after Dron i.v. may indicate an important second antiarrhythmic property.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10028928     DOI: 10.1097/00005344-199902000-00006

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes.

Authors:  Elke Detre; Morten B Thomsen; Jet D Beekman; Karl-Uwe Petersen; Marc A Vos
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

2.  The JT-area indicates dispersion of repolarization in dogs with atrioventricular block.

Authors:  Jurren M van Opstal; S Cora Verduyn; Stephan K G Winckels; Hendrik M Leerssen; Jet D M Leunissen; Hein J J Wellens; Marc A Vos
Journal:  J Interv Card Electrophysiol       Date:  2002-06       Impact factor: 1.900

3.  Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone.

Authors:  A Varró; J Takács; M Németh; O Hála; L Virág; N Iost; B Baláti; M Agoston; A Vereckei; G Pastor; M Delbruyère; P Gautier; D Nisato; J G Papp
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

4.  The anaesthetized rabbit with acute atrioventricular block provides a new model for detecting drug-induced Torsade de Pointes.

Authors:  Mihoko Hagiwara; Seiji Shibuta; Kazuhiro Takada; Ryuichi Kambayashi; Misako Nakajo; Megumi Aimoto; Yoshinobu Nagasawa; Akira Takahara
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

Review 5.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

Review 6.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 7.  Novel approaches for pharmacological management of atrial fibrillation.

Authors:  Joachim R Ehrlich; Stanley Nattel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 8.  Dronedarone.

Authors:  Sheridan M Hoy; Susan J Keam
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

9.  Gap junction heterogeneity as mechanism for electrophysiologically distinct properties across the ventricular wall.

Authors:  Maria Strom; Xiaoping Wan; Steven Poelzing; Eckhard Ficker; David S Rosenbaum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-24       Impact factor: 4.733

10.  Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter.

Authors:  Gerald V Naccarelli; Deborah L Wolbrette; Vadim Levin; Soraya Samii; Javier E Banchs; Erica Penny-Peterson; Mario D Gonzalez
Journal:  Clin Med Insights Cardiol       Date:  2011-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.